Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2014 | short review

ASH 2013: short review on myeloproliferative neoplasms

verfasst von: Stefan Schmidt, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

At the 2013 annual meeting of the American Society of Hematology, the role of calreticulin in essential thrombocythemia and primary myelofibrosis as well as safety aspects in second-generation tyrosin kinase inhibitor treatment of chronic myeloid leukemia have been major issues in the field of myeloproliferative neoplasms.
Vorheriger Artikel Myelodysplastic syndromes (MDS)
Nächster Artikel ASH Update 2013: chronic lymphocytic leukemia and indolent lymphoma
Literatur
1.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.PubMedCrossRef
2.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405.PubMedCrossRefPubMedCentral
3.
Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714–9.PubMedCrossRef
4.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8.PubMedCrossRef
5.
Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014 Aug;89(8):E121-4. doi: 10.1002/ajh.23743.
6.
Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014. doi:10.1038/leu.2014.100.
7.
Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552–5.PubMed
8.
Saglio G, Hochhaus A, Hughes TP, Clark RE, Nakamae H, Kim D-W, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes. Blood. 2014;122(21); abstract #92.
9.
Cortes JE, Hochhaus A, Kim D-W, Shah NP, Mayer J, Rowlings P, et al. Four-year (Yr) follow-up of patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood. 2014;122(21); abstract #653.
10.
Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9.PubMedCrossRef
11.
Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Grebien F, Eisenwort G, Schgoer W, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood. 2014;122(21); abstract #257.
12.
le Coutre P, Hughes TP, Mahon F-X, Kim D-W, Steegmann JL, Shah NP, et al. Peripheral arterial occlusive disease (PAOD) in patients (Pts) receiving dasatinib: experience across multiple clinical trials. Blood. 2014;122(21); abstract #1489.
13.
Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37.PubMedCrossRef
14.
Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib in patients (pts) with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 2-year follow-up of the PACE trial. Blood. 2014;122(21); abstract #650.
15.
Brümmendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim D-W, Conlan MG, et al. Bosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 48-month update. Blood. 2014;122(21); abstract #2723.
16.
Cortes JE, Kantarjian HM, Khoury HJ, Brümmendorf TH, Conlan MG, Wang K, et al. Long-term evaluation of vascular toxicity in patients with Ph + leukemias treated with bosutinib. J Clin Oncol. 2014;32(15); abstract #7060.
Metadaten
Titel
ASH 2013: short review on myeloproliferative neoplasms
verfasst von
Stefan Schmidt, MD
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0168-2

Weitere Artikel der Ausgabe 3/2014

Molecular monitoring of minimal residual disease in acute leukemia

  • short review

The challenge of soft tissue sarcomas—critical aspects of therapies with curative intent

  • editorial

Surgical aspects in the treatment of retroperitoneal soft tissue sarcomas

  • short review

Importance of intraoperative radiation therapy in the treatment of soft tissue sarcoma: data at hand

  • review

ASH 2013: constant progress: not only for B-cell neoplasms

  • editorial

The role of maintenance strategies in breast cancer

  • short review